Actavis

(

ACT

) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.9%. By the end of trading, Actavis rose $2.57 (2.1%) to $125.86 on average volume. Throughout the day, 1,627,498 shares of Actavis exchanged hands as compared to its average daily volume of 1,652,200 shares. The stock ranged in a price between $123.70-$126.47 after having opened the day at $123.92 as compared to the previous trading day's close of $123.29. Other companies within the Drugs industry that increased today were:

ZIOPHARM Oncology

(

ZIOP

), up 16.2%,

Cytokinetics

(

CYTK

), up 11.1%,

Intercept Pharmaceuticals

(

ICPT

), up 9.8% and

Zalicus

(

ZLCS

), up 9.5%.

Actavis, Inc., an integrated specialty pharmaceutical company, engages in developing, manufacturing, marketing, selling, and distributing generic, branded generic, brand, biosimilar, and over-the-counter pharmaceutical products worldwide. Actavis has a market cap of $15.5 billion and is part of the health care sector. Shares are up 43.4% year to date as of the close of trading on Wednesday. Currently there are 13 analysts that rate Actavis a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates

Actavis

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front,

Mast Therapeutics

(

MSTX

), down 37.2%,

Peregrine Pharmaceuticals

(

PPHM

), down 23.1%,

PTC Therapeutics

(

PTCT

), down 15.1% and

Oragenics

(

OGEN

), down 11.5% , were all laggards within the drugs industry with

Sarepta Therapeutics

(

SRPT

) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null